Application of hericium erinaceus polypeptide in preparation of product for regulating gastric mucosa flora

Abstract

The application belongs to the technical field of edible fungi, and relates to application of Hericium erinaceus polypeptide in preparation of products for regulating gastric mucosa flora. The application provides application of Hericium erinaceus polypeptide in preparation of products for regulating gastric mucosa flora, and an amino acid sequence of the Hericium erinaceus polypeptide is shown as SEQ ID NO. 1. The Hericium erinaceus polypeptide can regulate gastric mucosa flora after Helicobacter pylori infection, relieve the effect of gastritis, has a pathological repair effect on liver and stomach tissue infected by Helicobacter pylori, plays a role in protecting gastric mucosa barrier, and can increase expression of tight junction proteins.

Description

Technical Field

[0001] This invention belongs to the field of edible fungi technology, specifically relating to the application of Hericium erinaceus polypeptide in the preparation of products that regulate gastric mucosal flora. Background Technology

[0002] Lion's mane mushroom ( Hericium erinaceus (Bull.) Pers. is a fungus belonging to the family Hericaceae and the genus Hericium. Hericium erinaceus is considered both a prized edible food and an important medicinal fungus in China. Modern research indicates that it contains active ingredients such as polypeptides, polysaccharides, fats, and proteins, which have certain therapeutic effects on digestive tract tumors, gastric and duodenal ulcers, gastritis, and abdominal distension. However, the specific functions of the individual components extracted from Hericium erinaceus have not yet been fully reported using current technology. Summary of the Invention

[0003] The purpose of this invention is to provide the application of Hericium erinaceus polypeptide in the preparation of products that regulate gastric mucosal flora. Specifically, this invention provides a Hericium erinaceus pentapeptide; said Hericium erinaceus pentapeptide has the function of regulating gastric mucosal flora.

[0004] This invention provides the application of Hericium erinaceus polypeptide in the preparation of products that regulate gastric mucosal flora, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0005] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of products that regulate the gastric mucosal flora after Helicobacter pylori infection, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0006] Preferably, the product is a drug.

[0007] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of anti-inflammatory drugs, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0008] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug for protecting the gastric mucosal barrier, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0009] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug that increases the expression of gastric mucosal tight junction protein, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1; wherein the gastric mucosal tight junction protein includes one or more of Oclaudin, Claudin and ZO-1.

[0010] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug for treating gastritis, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0011] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug for treating gastritis caused by Helicobacter pylori infection, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0012] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug with a repairing effect on the liver and / or stomach, wherein the amino acid sequence of the Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0013] Preferably, the liver and / or stomach includes a liver and / or stomach infected with Helicobacter pylori.

[0014] This invention provides the application of Hericium erinaceus polypeptides in the preparation of products that regulate gastric mucosal flora. The Hericium erinaceus polypeptides described in this invention can regulate the gastric mucosal flora after Helicobacter pylori infection, alleviating gastritis; they also have a pathological repair effect on Helicobacter pylori-infected liver and stomach tissues; and they protect the gastric mucosal barrier by increasing the expression of tight junction proteins. Attached Figure Description

[0015] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0016] Figure 1 PCoA analysis and PCA analysis results diagram provided for this invention; Figure 2 The relative abundance of gastric microbiota at the phylum level is shown in the figure provided by this invention. Figure 3 A graph showing the gene expression changes of tight junction proteins in the gastric mucosa provided by this invention; Figure 4 A slice of gastric tissue provided for this invention; Figure 5 A slice of liver tissue provided for this invention. Detailed Implementation

[0017] This invention provides the application of Hericium erinaceus polypeptide in the preparation of products that regulate gastric mucosal flora, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1: KSPLY.

[0018] This invention also provides the application of Hericium erinaceus polypeptide in the preparation of a product that regulates the gastric mucosal flora after Helicobacter pylori infection, wherein the amino acid sequence of the Hericium erinaceus polypeptide is shown in SEQ ID NO.1. In this invention, the product is preferably a pharmaceutical product. The Hericium erinaceus polypeptide of this invention can regulate the gastric mucosal flora after Helicobacter pylori infection, thereby alleviating gastritis.

[0019] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of anti-inflammatory drugs, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0020] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug for protecting the gastric mucosal barrier, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0021] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug that increases the expression of gastric mucosal tight junction protein, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1; wherein the gastric mucosal tight junction protein includes one or more of Oclaudin, Claudin and ZO-1.

[0022] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug for treating gastritis, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0023] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug for treating gastritis caused by Helicobacter pylori infection, wherein the amino acid sequence of Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0024] The present invention also provides the application of Hericium erinaceus polypeptide in the preparation of a drug with a repairing effect on the liver and / or stomach, wherein the amino acid sequence of the Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

[0025] In this invention, the liver and / or stomach includes a liver and / or stomach infected with Helicobacter pylori.

[0026] To further illustrate the present invention, the application of the Hericium erinaceus polypeptide provided by the present invention in the preparation of products that regulate gastric mucosal flora is described in detail below with reference to the accompanying drawings and embodiments, but these should not be construed as limiting the scope of protection of the present invention.

[0027] Example 1 Establishing a mouse model of Helicobacter pylori gastritis by gavage Experimental mice: 5-week-old healthy male C57BL / 6 mice (18-20g); mice were allowed free access to food and water. After one week of acclimatization, the NC group was administered brain and heart extract by gavage, and the HP group was administered Helicobacter pylori SS1 brain and heart extract by gavage. Each mouse was administered 0.2 ml by gavage once every other day for a total of 5 times. Two weeks after the end of the Helicobacter pylori gavage, a mouse model of Helicobacter pylori infection was established.

[0028] Subsequently, the HP group was randomly divided into 3 groups, with the two experimental groups receiving oral administration of 200 mg / kg / time (low dose) and 400 mg / kg / time (high dose) of polypeptide, respectively. The blank control group (NC) and the Helicobacter pylori infection control group (HP) received oral administration of an equal volume of physiological saline once a day for 2 weeks. After that, the mice were fasted overnight and euthanized.

[0029] The mice were grouped as follows: NC-healthy mice: equal volume of physiological saline; HP-Helicobacter pylori-infected mice: equal volume of physiological saline; LK-low-dose peptide intervention in Helicobacter pylori-infected mice: 200 mg / kg / dose; HK-High-dose peptide intervention in Helicobacter pylori-infected mice: 400 mg / kg / dose.

[0030] Example 2 Omics analysis of gastric mucosal microbiota in mice Gastric contents and gastric mucosa were collected from each group, and 16S rRNA was sequenced to screen for differentially expressed bacteria.

[0031] NC-healthy mice: equal volume of physiological saline; HP-Helicobacter pylori-infected mice: equal volume of physiological saline; LK-low-dose peptide intervention in Helicobacter pylori-infected mice: 200 mg / kg / dose; HK-High-dose peptide intervention in Helicobacter pylori-infected mice: 400 mg / kg / dose.

[0032] PCoA analysis and PCA analysis are both bar graph analyses, which can reflect the differences in community composition among different groups. Figure 1 It can be seen that the NC and HP groups can be clearly distinguished. After the addition of low-dose and high-dose peptide intervention, the gastric flora of mice can move towards the direction of the healthy NC group, indicating that peptides can change the gastric flora structure of Helicobacter pylori-infected mice.

[0033] Figure 2The graph shows the relative abundance of gastric microbiota at the phylum level. At the phylum level, there were significant changes in the relative abundance of microbiota between the NC and HP groups. Specifically, HP had a higher relative abundance of Firmicutes and Proteobacteria than the NC group, while HP had a lower relative abundance of Bacteroides and Actinobacteriota than the NC group. Mice infected with Helicobacter pylori and fed low-dose and high-dose peptides showed a decrease in the relative abundance of Firmicutes and Proteobacteria, and an increase in the relative abundance of Bacteroides and Actinobacteriota in their gastric microbiota compared to the HP group. Compared to the HP group, the peptide treatment group significantly regulated the relative abundance of beneficial microbiota in the gastric mucosa, making the microbiota in the peptide group similar to that in the control group.

[0034] Example 3 qRT-PCR validation of gene expression of tight junction proteins in gastric mucosa RNA was extracted from mouse gastric mucosa using the Trizol method, reverse transcribed into cDNA, and then verified by qRT-PCR. The results are as follows: Figure 3 As shown in the figure. Verification revealed that the peptide treatment group could increase the gene expression of tight junction proteins to protect the gastric mucosal barrier.

[0035] Example 4 Mouse stomach and liver sections, HE staining, and pathological analysis Gastric mucosa and liver tissue were collected from each group, and after sectioning and hematoxylin and eosin (HE) staining, the tissue was photographed under a 400x microscope and then subjected to pathological analysis. Figure 4 The results showed that the gastric chief cells in the NC group were neatly arranged with no obvious cell damage (black arrows), and the submucosa and muscularis propria were clearly defined without obvious pathological changes. In the HP group, obvious apoptosis was observed (red arrows), accompanied by a small amount of lymphocyte infiltration (yellow arrows). Compared to the HP group, the Hericium erinaceus polypeptide treatment group could repair the pathological damage to gastric tissue caused by HP infection. In the Hericium erinaceus polypeptide treatment groups LK and HK, the gastric chief cells were relatively tightly arranged with intact cell structure (black arrows), and occasional gastric cell apoptosis was observed (red arrows).

[0036] Figure 5The results showed that in the NC group, hepatocytes were neatly arranged and structurally intact (black arrows), with no obvious abnormalities observed in the portal areas between adjacent hepatic lobules, and no significant necrosis or inflammatory cell infiltration. In the HP group, focal necrosis of hepatocytes was observed around the central vein, accompanied by a small amount of granulocyte and lymphocyte infiltration (blue arrows). Hepatocyte nuclei were fragmented and cytoplasm disintegrated (yellow arrows). Due to hepatocyte apoptosis, the hepatocytes were loosely arranged, with numerous blank areas (red arrows). Compared to the HP group, the LK and HK groups treated with Hericium erinaceus polypeptides could repair HP-induced pathological damage to liver tissue. Hepatocytes were relatively tightly arranged and structurally intact (black arrows), with no obvious inflammatory cell infiltration. The fragmentation of hepatocyte nuclei and cytoplasm disintegration (yellow arrows) were alleviated, and occasional gaps due to partial hepatocyte apoptosis were observed (red arrows).

[0037] Peptide treatment can effectively alleviate gastric and liver tissue lesions following Helicobacter pylori infection.

[0038] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. The use of a Hericium erinaceus polypeptide in the preparation of a drug for treating gastritis caused by Helicobacter pylori infection, wherein the amino acid sequence of the Hericium erinaceus polypeptide is shown in SEQ ID NO.1.

Images